Researchers employing artificial intelligence have achieved unprecedented success designing novel peptides with potential therapeutic applications, transforming traditional drug discovery pathways. AI models have outperformed expectations in predicting and generating stable peptide structures, accelerating the identification of candidates that might modulate RNA-binding proteins and other targets previously challenging for drug development. Despite environmental and synthetic challenges, the integration of AI promises to reshape peptide therapeutics and sustainability in pharmaceutical manufacturing.